Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Top Cited Papers
- 1 October 2019
- journal article
- review article
- Published by Elsevier BV in The Lancet Diabetes & Endocrinology
- Vol. 7 (10), 776-785
- https://doi.org/10.1016/s2213-8587(19)30249-9
Abstract
No abstract availableKeywords
Funding Information
- University of Oxford (RE/13/1/30181)
- BHF Centre of Research Excellence, Oxford (RE/18/6/34217)
This publication has 29 references indexed in Scilit:
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2016
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitusNature Reviews Endocrinology, 2016
- Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonistsDiabetes, Obesity and Metabolism, 2015
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary SyndromeThe New England Journal of Medicine, 2015
- Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similaritiesEuropean Journal of Internal Medicine, 2014
- The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility IndexJournal of Clinical Epidemiology, 2014
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)Diabetic Medicine, 2009
- Biology of Incretins: GLP-1 and GIPGastroenterology, 2007
- Calculating the number needed to treat for trials where the outcome is time to an eventBMJ, 1999